Scholarlink

<p>Prostate cancer is the most common malignancy in men. Although frequently diagnosed at localized stages, a substantial proportion present high-risk features associated with biochemical recurrence and progression. In non-metastatic hormone-sensitive prostate cancer (nmHSPC), standard treatment has traditionally consisted of local therapy combined with androgen deprivation therapy (ADT), but recent advances have reshaped the therapeutic landscape. The addition of androgen receptor pathway inhibitors (ARPIs) to ADT has demonstrated substantial survival benefits in metastatic hormone-sensitive disease, providing the rationale for exploring treatment intensification in earlier stages. Modern imaging techniques, particularly PSMA PET, enable detection of occult metastatic disease influencing treatment selection. Emerging evidence from randomized and phase II–III studies suggests that ARPI intensification combined with radiotherapy, surgery, or salvage approaches may improve disease control in selected high-risk nmHSPC populations. This narrative review summarizes the evidence supporting ARPI intensification in nmHSPC and discusses the clinical implications of recent advances.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Androgen receptor pathway inhibitor intensification in non-metastatic hormone-sensitive prostate cancer: current evidence and clinical implications

  • 期刊论文

  • 发表日期：

    2026年4月10日

查看全文
  • Patricia Willisch,
  • Beatriz Vázquez-Barreiro,
  • Ana Plata,
  • Irene Cienfuegos Belmonte,
  • Gloria Guardia,
  • Rocío del Castillo-Acuña,
  • Giulio Francolini,
  • Ciro Franzese,
  • José Daniel Subiela Henríquez,
  • Felipe Couñago,
  • Fernando López-Campos

摘要

Prostate cancer is the most common malignancy in men. Although frequently diagnosed at localized stages, a substantial proportion present high-risk features associated with biochemical recurrence and progression. In non-metastatic hormone-sensitive prostate cancer (nmHSPC), standard treatment has traditionally consisted of local therapy combined with androgen deprivation therapy (ADT), but recent advances have reshaped the therapeutic landscape. The addition of androgen receptor pathway inhibitors (ARPIs) to ADT has demonstrated substantial survival benefits in metastatic hormone-sensitive disease, providing the rationale for exploring treatment intensification in earlier stages. Modern imaging techniques, particularly PSMA PET, enable detection of occult metastatic disease influencing treatment selection. Emerging evidence from randomized and phase II–III studies suggests that ARPI intensification combined with radiotherapy, surgery, or salvage approaches may improve disease control in selected high-risk nmHSPC populations. This narrative review summarizes the evidence supporting ARPI intensification in nmHSPC and discusses the clinical implications of recent advances.